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Background: Sentinel lymph node (SLN) mapping is the standard method for axillary lymph node staging in patients
with breast cancer. Blue dye and radioisotopes are commonly used agents to localize SLNs, but both have several
disadvantages. The purpose of this study was to evaluate magnetic resonance lymphography with a gadolinium-based
contrast agent (Gd-MRL) in sentinel lymph node identification and metastasis detection in patients with breast cancer.
Methods: Sixty patients (mean age: 46.2 ± 8.8 years) with stage T1- 2 breast cancer and clinically negative axillary lymph
nodes participated in this study. After 0.9 ml of contrast material and 0.1 ml of mepivacaine hydrochloride 1% were
mixed and injected intradermally into the upper-outer periareolar areas, axillary lymph flow was tracked and sentinel
lymph nodes were identified by Gd-MRL. After SLN biopsy and/or surgery, the efficacy of SLN identification and
metastasis detection of Gd-MRL were examined.
Results: Ninety-six lymph nodes were identified by Gd-MRL as SLNs (M-SLN), and 135 lymph nodes were detected by
blue dye-guided methods as SLNs (D-SLN). There was a strong correlation (P < 0.001) between the SLN numbers found
by these two methods. Using blue dye-guided methods as the gold standard, the sensitivity of Gd-MRL was 95.65%
and the false-negative rate was 4.3% for axillary lymphatic metastasis detection. With heterogeneous enhancement
and enhancement defect as the diagnostic criteria, Gd-MRL gave a sensitivity of 89.29% and specificity of 89.66% in
discriminating malignant from benign SLNs.
Conclusion: Gd-MRL offers a new method for SLN identification and metastasis detection in patients with breast cancer.
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Breast cancer is the second leading cause of death from
cancer, with more than 200,000 new cases diagnosed
each year in the United States [1]. The regional spread
of tumor cells from the breast primary lesion to the axil-
lary lymph nodes is a well-recognized step in the meta-
static process for breast cancer [2]. Therefore, accurate
detection of axillary lymph node metastases is critical* Correspondence: jhu@med.wayne.edu; wangjian_811@yahoo.com
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unless otherwise stated.for surgical planning, adjuvant therapy planning, and
prognostication.
Histopathological examination of sentinel lymph node
biopsy (SLNB) is the standard procedure in the determin-
ation of axillary lymph node status [3,4]. Radioisotopes
(such as technetium-99 m sulfur colloid and technetium-
99 m albumin) and blue dyes (such as isosulfan blue or
patent blue) are widely utilized as lymphatic mapping
agents. However, the use of radioisotopes is associated
with radiation exposure/safety issues for the patient, sur-
geon, pathologist, and other medical staff, and there may
be limited availability of radioisotope (technetium-99 m)
and gamma detection probe equipment at some hospitals
that do not have nuclear medicine capabilities [5,6]. Blueis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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operative lymphatic mapping. However, intraoperative
lymphatic mapping with blue dyes can be associated
with allergic/anaphylactic reactions, and lacks the abil-
ity to visualize the pre-incision anatomical relationship
between tumor, lymph vessels, and SLNs, thus limiting
the surgeon’s ability to decide upon exact placement of
the surgical incision [7-9]. Therefore, a safe, simple and
non-invasive preoperative method is needed in clinical
practice.
Magnetic resonance lymphography (MRL) is a technique
that employs magnetic resonance imaging after interstitial
injection of a contrast agent [10-15]. In a past study, we
have established an effective MRL protocol with gado-
linium (Gd)-based contrast agents (Gd-MRL) that can
generate high-resolution images of axillary lymphatic
vessels and nodes [16]. The purpose of this study was to
evaluate Gd-MRL in sentinel lymph node (SLN) identi-




All research procedures were approved by the ethics com-
mission of Southwest Hospital of China and were con-
ducted in accordance with the Declaration of Helsinki.
Written informed consent was obtained for all patients.
Patients
From January 2012 to Oct 2013, a total of 68 consecutive
patients with stage T1- 2 breast cancer and clinically nega-
tive axillary lymph nodes who underwent sentinel lymph
node biopsy were enrolled in this study. Patients with
multiple primary tumors, prior axillary surgery, preopera-
tive chemotherapy, or who were pregnant were excluded.
Patients with a contraindication to MR imaging or a
known allergy to the contrast agents were also excluded.
The study population comprised 60 patients (age ranging
from 31 years to 62 years; mean age: 46.2 ± 8.8 years), in-
cluding 47 with invasive ductal carcinoma, 10 with inva-
sive lobular carcinoma, 2 with tubular carcinoma and 1
with medullary carcinoma.
Contrast agent and administration
Gadopentetate dimeglumine (GD-DPTA) (Magnevist, Bayer
Schering Pharma AG, Berlin, Germen) with a gadolinium
(Gd) concentration of 0.5 mol/L was used for contrast.
A 1-ml tuberculin syringe and 26-gauge needle were used
for Gd-DPTA injection. A total of 0.9 ml contrast material
and 0.1 ml mepivacaine hydrochloride 1% were mixed and
injected intradermally into the upper-outer periareolar
areas [17]. Mepivacaine hydrochloride was added to al-
leviate pain during intradermal injection. The injectionsite was massaged gently for 90 seconds to promote
migration.MRI
MR imaging for all subjects was performed on a 3.0 T
whole-body system (Magnetom Trio, Siemens Healthcare,
Erlangen, Germany) with a 12-channel matrix body coil.
Patients were placed in the supine position with their
arms elevated, similar to the position used during surgery.
The conventional imaging protocol consisted of an axial
T1-weighted fast spin echo (T1-FSE) sequence, an axial
diffusion-weighted sequence (TR/TE 6548/65 ms; FOV
340 × 340 mm2; b values of 50, 200 and 500 sec/mm2),
and an axial T2-weighted fat-suppressed sequence (TR/
TE 4000/70 ms; inversion delay 125 ms; flip angle 90°; FOV
340× 340 mm2). For Gd- MRL, 3D fast spoiled gradient-
recalled echo T1-weighted images with fat saturation
(volumetric interpolated breath-hold examination, VIBE)
were acquired prior to the administration of Gd-DTPA
with the following parameters: TR/TE = 8.0/3.9, flip angle
15°, FOV = 340 mm× 340 mm, acquisition matrix = 512 ×
512, slice thickness = 1 mm. After intradermal administra-
tion of the contrast material, the same imaging sequence
(VIBE) was repeated at 9, 12, 15, 18, 21 and 24 minutes.
Maximum-intensity projections were used to improve
visualization of lymphatic vessels. Finally, a bolus intra-
venous injection of 0.1 mmol/kg gadopentetate dime-
glumine followed by a 20 ml saline flush at an injection
rate of 2 ml/s was administered, and the sequence was
repeated.SLN identification and skin marking
During scanning, lymph vessels from the injection site
to the axilla were stained with Gd-MRL. For Gd-MRL,
the SLN was defined as the first lymph node visualized
on the lymph vessel draining directly from the injection
site (M-SLN) . In some patients, more than one lymph-
atic vessel drained directly from the injection site. In
these patients, the first visualized lymph node along each
lymphatic vessel draining directly from the injection site
was considered a sentinel node (M-SLN). [17]. The mark-
ing of the M-SLN spot was performed using a skin-marker
method [18,19]. A cod liver oil capsule, which is usually
used for MRI localization, was first attached to the skin.
After 3D Gd-MRL images were reconstructed at each
time point with maximum-intensity projection and surface-
rendering techniques, the distance and angle between the
marker and the M-SLN were analyzed, and the marker was
adjusted appropriately. Usually, 2–3 scans were needed
to get an accurate correspondence between the M-SLN
and the skin oil marker. Finally, the M-SLN location was
marked on the skin surface using an oil painting pen.
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Sentinel lymph node biopsy was performed for all pa-
tients. After the induction of general anesthesia, a subar-
eolar injection of 3 ml methylene blue was performed,
and the injection site was massaged gently for 90 seconds
to promote migration using the same technique as for
MR lymphography. M-SLNs located just under the mark-
ing site determined by MR lymphography were removed
first. If several nodes lay close to others, they were dis-
criminated by size and morphological character. Then,
other SLNs stained by methylene blue were detected and
excised by following the blue lymphatic vessels. These
were designated as D-SLN. All dissected M-SLNs and
their MRI images were examined to confirm they were
identical or closely similar in shape and size. All of the
resected LNs were fixed in formalin, 2-mm serial sec-
tions were prepared, and histopathologic evaluations
were made for the presence of cancer metastasis. If no
SLN metastases were present, LN dissection was not
performed, but when there were metastases in resected
SLNs, it was.Data analysis
Two radiologists with 10 and 12 years of experience in
breast imaging analyzed the images prospectively. Corre-
lations between the number of SLNs detected by Gd-
MRL and the blue dye-guided method were analyzed.
Heterogeneous enhancement and enhancement defect are
characters of metastatic nodes in Gd-MRL, as shown by
our past study [16]. According to these criteria, the SLN
metastasis diagnostic ability, including sensitivity and
specificity of Gd-MRL, were calculated. All statistics were
computed using SPSS statistical software (version 16.0,
SPSS Inc., Chicago, Illinois). P values of 0.05 were con-
sidered statistically significant.Figure 1 Gd-MRL images in a 46-year-old patient with left breast duc
lymphatic pathway was dynamically stained 9 min (B) and 18 min after co
(white thin arrow). One distant node (white thick arrow) and its connectionResults
All breast cancer patients completed their examinations
successfully. Six showed swelling at the site of contrast
injection, and all of them disappeared within approximately
30 minutes. There was no allergic or other acute reaction.
Sentinel lymph nodes could not be delineated on pre-
injection MR imaging (Figure 1 A). After injection of
Gd-DTPA into the subareolar breast tissue, the dynamic
multiple-angle views of the 3D Gd-MRL image showed
the axillary lymph flowing into the SLN (Figure 1 B, C).
The SLN could be identified easily on Gd-MRL. Distant
nodes and their connection lymph vessel with SLNs were
also displayed (Figure 1 C).
In total, 96 lymph nodes were identified by Gd-MRL
as M-SLNs and marked on the skin. At times, there were
several lymph vessels draining from the injection site, so
there were more SLNs than patients. Another 121 nodes
were identified by Gd-MRL as distant lymph nodes. During
operation, all M-SLNs were easily resected under the guid-
ance of skin marker and 3D MR imaging (Figure 2), and
135 lymph nodes were detected by blue dye as D-SLNs.
There was a strong correlation between the numbers of
SLNs identified by the two methods (average M-SLNs
1.6 ± 0.6, average D-SLNs 2.25 ± 1.18, Spearman rank
correlation coefficient 0.68, P < 0.001). Three MRI-detected
SLNs were not stained by blue dye.
During surgery, all SLNs identified by either Gd-MRL or
the blue dye-guided method were removed, with an average
of 2.36 per patient. Twenty-three patients had confirmed
metastasis by blue dye-guided method; in 22 of these 23 pa-
tients, SLN metastasis was detected by Gd-MRL. Using the
blue dye-guided method as the gold standard, the sensitivity
of Gd-MRL was 95.65% and the false negative rate was
4.3% for axillary lymphatic metastasis detection.
In Gd-MRL imaging, 28 M-SLNs were confirmed to
have metastases; 25 of them showed heterogeneoustal carcinoma. Compared with pre-contrast images (A), the axillary
ntrast injection (C). The SLN could be easily identified on Gd-MRL
lymph vessel (white triangle) with an SLN are also displayed.
Figure 2 In a 42-year-old patient with right breast ductal carcinoma. A: The skin marker of a cod liver oil capsule (white arrow) was attached to
the skin. B: The skin marker (white arrow) correlated well with the target lymph node (white triangle). C, D: During operation, the lymph node was
easily resected under the guidance of the skin marker.
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geneous enhancement and enhancement defect as the
diagnostic criteria, Gd-MRL gave a sensitivity of 89.29%
and specificity of 89.66% in discriminating malignant
from benign SLNs (Figure 3). Three of 28 Gd-MRL de-
tected SLNs were confirmed metastatic by pathology,
but these were not diagnosed correctly by Gd-MRL due
to the small metastasis size (3, 4 and 3 mm). Of the 6
false-positive results, all were attributable to heteroge-
neous distribution of Gd contrast.
Discussion
Accurate staging of the axillary lymph node status for
breast cancer patients is critical for surgical planning, ad-
juvant therapy planning, and prognostication. The deter-
mination of a negative axillary lymph node status is highly
important, as it eliminates the need for the performance
of an axillary lymph node dissection, which is well known
to be associated with the occurrence of lymphedema, pain,Figure 3 Comparison of MRL images between benign and malignant
carcinoma. The lymph node displays homogeneous enhancement (white t
left breast ductal carcinoma. Heterogeneous enhancement and enhancemnumbness, and range of motion limitations to the shoul-
der region [20-22]. The sentinel lymph node (s) is the first
lymph node or first group of lymph nodes to receive
lymphatic drainage from the site of the tumor or the site
of injection of the sentinal lymph node localizing agent; if
negative, the SLN predicts the status of the remaining
distant nodes.
Histopathological examination of sentinel lymph node
biopsy is the standard procedure to detect axillary lymph
node metastasis. Both radioisotope (technetium-99 m)
and blue dyes (isosulfan blue or patent blue) are widely
used for lymphatic mapping and SLN identification. The
combination of blue dye and radioisotope has a higher
SLN identification rate than that of blue dye alone;
however, there is no significant difference in the SLN
identification rate between blue dye alone versus radioiso-
tope alone [23,24]. However, the radioguided approach
to SLN identification requires utilization of radioisotope
(technetium-99 m) and gamma detection probe equipmentSLNs. A: Benign SLN in a 41-year-old woman with left breast ductal
riangle) in Gd-MRL. B, C: Malignant SLNs in a 48-year-old woman with
ent defect were found in Gd-MRL (white arrows).
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medicine capabilities. When blue dye alone is utilized for
intraoperative SLN identification, the surgeon lacks any
specific cues as to the anatomic location of SLNs prior to
making the surgical incision. Thus, the lack of being able
to visualize the pre-incision anatomical relationship be-
tween tumor, lymph vessels, and SLNs when using the blue
dye alone approach limits the surgeon’s ability to decide as
to where to place the surgical incision. The Gd-MRL ap-
proach to SLN identification employs magnetic resonance
imaging after interstitial injection (i.e., intradermal periar-
eolar injection) of a conventional gadolinium-based agent.
Previously, we developed an effective clinical protocol that
can generate high-resolution images of axillary lymphatic
vessels and lymph nodes. In our current study, Gd-MRL
clearly showed the lymphatic flow from the intradermal
periareolar injection site to the axillary region, and result-
ant identification of the SLNs. The SLNs identified by the
Gd-MRL approach correlated well with those SLNs identi-
fied by the blue dye alone approach. Using the blue dye
alone approach as an acceptable standard of care approach
to SLN identification, the sensitivity of the Gd-MRL ap-
proach was 95.65% and the false-negative rate was 4.3% for
axillary lymph node metastasis detection, indicating that
the Gd-MRL approach for breast cancer SLN identification
may be clinically feasible and result in an axillary lymph
node metastasis detection rate that may be acceptable for
use in clinical practice.
In this study, fewer SLNs were detected by Gd-MRL
than by the blue dye-guided method. The reason is that
in the blue dye-guided method, all dyed nodes were re-
moved as sentinel nodes according to their definition.
However, most of them were probably not sentinel
nodes, but distant nodes. It is difficult to differentiate
these by the standard procedure of sentinel node biopsy
using the blue dye-guided method [25]. In contrast,
Gd-MRL can accurately discriminate sentinel nodes from
distant nodes by visualizing and tracking the lymph flow,
which is essential to reduce the false-negative rate. These
results may indicate that the accuracy of Gd-MRL is better
than that of blue dye-guided methods for SLN identifica-
tion and has some advantages for SLN biopsy.
Recently, superparamagnetic iron oxide (SPIO)-MR lym-
phography and iopamidol-CT lymphography with intersti-
tial injection of contrast agent for breast cancer has
been reported. Compared with SPIO-MRL, Gd-MRL is
more economical and convenient. Superparamagnetic
iron oxide is a negative contrast and thus cannot image
the lymph vessel. Compared with iopamidol-CT lymphog-
raphy, Gd-MRL lacks radiation exposure, possibility of
anaphylactic shock and nephrotoxic impairment [26,27].
Localization of SLNs in the prone position of MRI dif-
fers from that in the operative (supine) position. Several
authors have emphasized the importance of preoperativeMR imaging in the supine position [28,29]. In the present
study, the supine position with elevation of the arms and
an MR marking technique using commercially available
tablets was adopted for precise preoperative simulation.
During surgery, our method was effective, and SLNs could
be easily resected under the guidance of skin markers.
In this study, Gd-MRL not only identified SLNs but
also diagnosed lymph node metastasis accurately. On a
node-by-node basis, using histopathology as the gold stand-
ard, Gd-MRL gave a sensitivity of 89.29% and specificity of
89.66%. Previous MR imaging with SPIO-MRL has demon-
strated a sensitivity of 84.0% and specificity of 90.9% for the
detection of metastasis in SLNs [26]. Our results are con-
sistent with this. Compared with other techniques that have
been developed to stage axillary lymphatic node metastases,
including dynamic contrast-enhanced MRI and diffusion-
weighted imaging techniques, Gd-MRL is more accurate
[30-32]. In this study, 3 SLNs with metastases were not di-
agnosed by Gd-MRL because the metastatic lesion was too
small (3, 4 and 3 mm) for the resolution of MRI. Thinner
section thickness may improve this.
This study has several limitations. First, there are
technical challenges for precise skin marking and SLN
correlation, which could not be resolved thoroughly in
all MRI studies of axillary lymph nodes [26,27]. What
we did was to correlate them based on the following
methods: 1) patients were placed in the supine position
with their arms elevated, similar to the position used dur-
ing surgery; 2) using a skin marker, which is usually used
for MRI localization; 3) during surgery, each node was re-
moved and correlated with a node on the MR image based
on its location. If several nodes lay close to others, they
were discriminated by size and morphological character.
This is an acceptable and effective method [33]. Second,
micrometastasis (<2 mm) was not considered in this
study. MR imaging has limited resolution in the present
setting and cannot reliably detect micrometastases in
lymph nodes. On the other hand, the clinical importance
of micrometastases is debatable [34]. Third, Gd-DTPA,
a clinically approved intravenous contrast material, was
injected in the subareolar breast tissue. Although this
off-label use was approved by the institutional review
board and all patients provided informed consent, the
intradermal toxicity or tolerance of Gd-DTPA needs fu-
ture investigation. Finally, we only evaluated intradermal
periareolar injection. Other possible injection sites, includ-
ing subareolar, subcutaneous over the primary tumor site,
peritumoral, and intratumoral, should be examined in the
future.
Conclusions
In conclusion, we have successfully identified axillary SLNs
and detected their metastases in breast cancer patients
using magnetic resonance lymphography with a widely
Li et al. BMC Cancer  (2015) 15:213 Page 6 of 6available Gd-based contrast agent in a typical clinical set-
ting. The high accuracy as well as the easy protocol sug-
gest a potential value in clinical practice.
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